Wunderlich Maintains Buy, $24 Target on Abiomed

Wunderlich Securities reiterates its Buy rating and $24 target price on Abiomed

on company strength on display at analyst meeting. Wunderlich says, “We have been extremely positive on the ABMD story, and while the shares have appreciated significantly of late, it was hard to walk away from Friday's meeting without a very positive opinion of the Abiomed story. Impella remains the clear focus of the story, and combined with the impressive R&D pipeline overview, the significant potential of Impella and longer-term opportunity for Symphony makes Abiomed one of the most attractive stories in the Medtech industry, in our opinion.” ABMD closed at $21.11 per share on Friday.